Psoriasis Clinical Trial

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Summary

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
Scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at Screening visit and Day 1
≥ 3% of Body Surface Area (BSA) involvement at Screening visit and Day 1
Evidence of plaque psoriasis in a non-scalp area
Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis

Exclusion Criteria:

Target Disease Exceptions:

Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

150

Study ID:

NCT05478499

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 34 Locations for this study

See Locations Near You

Burke Pharmaceutical Research
Hot Springs Arkansas, 71913, United States More Info
Dowling Stough, Site 0001
Contact
501-620-4449
Keck School of Medicine of University of Southern California
Los Angeles California, 90033, United States More Info
Maria Ochoa, Site 0042
Contact
323-442-0084
Dawes Fretzin Clinical Research Group, LLC
Indianapolis Indiana, 46250, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis Indiana, 46256, United States More Info
Scott Fretzin, Site 0007
Contact
317-516-5030
Skin Sciences, PLLC
Louisville Kentucky, 40217, United States More Info
Leon Kircik, Site 0041
Contact
502-451-9000
Lawrence J. Green, MD. LLC
Rockville Maryland, 20850, United States More Info
Lawrence Green, Site 0022
Contact
301-610-0663
ALLCUTIS Research, LLC
Beverly Massachusetts, 01915, United States More Info
David Greenstein, Site 0008
Contact
978-969-6897
Henry Ford Medical Center -
Bloomfield Hills Michigan, 48302, United States More Info
Linda Stein Gold, Site 0047
Contact
248-884-5356
Minnesota Clinical Study Center
Fridley Minnesota, 55432, United States More Info
Steven Kempers, Site 0002
Contact
763-571-4200
Psoriasis Treatment Center of Central NJ
East Windsor New Jersey, 08520, United States More Info
Jerry Bagel, Site 0049
Contact
160944345004434500
Forest Hill Dermatology Group
Kew Gardens New York, 11415, United States More Info
Jeffrey Weinberg, Site 0051
Contact
212-523-3808
Wake Forest University Health Sciences
Winston-Salem North Carolina, 27157, United States
Oregon Medical Research Center
Portland Oregon, 97223, United States More Info
Andrew Blauvelt, Site 0003
Contact
503-245-1525
UPMC Department of Dermatology
Pittsburgh Pennsylvania, 15213, United States More Info
Timothy Patton, Site 0005
Contact
412-647-2013
Center for Clinical Studies
Houston Texas, 77004, United States
Center for Clinical Studies
Houston Texas, 77004, United States More Info
Stephen Tyring, Site 0033
Contact
713-528-8818
Dermatology Clinical Research Center of San Antonio
San Antonio Texas, 78229, United States More Info
Steven Davis, Site 0004
Contact
210-614-0530
University of Utah MidValley Dermatology
Murray Utah, 84107, United States
Virginia Clinical Research , Inc
Norfolk Virginia, 23502, United States More Info
David Pariser, Site 0006
Contact
757-625-0151
Local Institution - 0019
Paris , 75010, France More Info
Site 0019
Contact
Local Institution - 0040
Romans sur Isere Cedex , 26102, France More Info
Site 0040
Contact
Local Institution - 0044
Rouen , 76031, France More Info
Site 0044
Contact
Local Institution - 0035
Mahlow Brandenburg, 15831, Germany
Local Institution - 0038
Witten Deutschland, 58454, Germany More Info
Site 0038
Contact
Local Institution - 0013
Frankfurt Hessen, 60590, Germany More Info
Site 0013
Contact
Local Institution - 0050
Luebeck Schleswig-Holstein, 23538, Germany
Local Institution - 0048
Hamburg , 20246, Germany More Info
Site 0048
Contact
Local Institution - 0012
Kiel , 24105, Germany More Info
Site 0012
Contact
Local Institution - 0011
Mahlow , 15831, Germany More Info
Site 0011
Contact
Local Institution - 0037
Lodz Woj.Lodzkie, 90-43, Poland
Local Institution - 0046
Lodz Woj.Lodzkie, 90-43, Poland
Local Institution - 0026
Krakow , 30438, Poland More Info
Site 0026
Contact
Local Institution - 0017
Lodz , 90-43, Poland More Info
Site 0017
Contact
Local Institution - 0014
Rzeszow , 35-00, Poland More Info
Site 0014
Contact
Local Institution - 0027
Rzeszow , 35-00, Poland
Local Institution - 0015
Wroclaw , 51-68, Poland More Info
Site 0015
Contact
Local Institution - 0036
Wroclaw , 51-68, Poland
Local Institution - 0031
London Greater London, SE1 9, United Kingdom More Info
Site 0031
Contact
Local Institution - 0045
Salford Greater Manchester, M6 8H, United Kingdom More Info
Site 0045
Contact
Local Institution - 0039
Southampton Hampshire, SO16 , United Kingdom More Info
Site 0039
Contact

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

150

Study ID:

NCT05478499

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.